Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST).
Rigorous validation of biomarkers for early detection of cancer differs at the National Institute of Standards and Technology (NIST) from similar processes common among research laboratories. As a newly discovered biomarker assay makes the transition from a research setting to the clinical diagnostic laboratory, it should progress through defined stages of assay confirmation. The first task of a validation laboratory is evaluation of research assay technology, performance, and specifications (analytical validation). However, the ultimate goal is initial validation of the test to identify early stage cancer (clinical validation). Upon technical and clinical confirmation, assays are moved systematically toward a standardized, reproducible, high-throughput format for clinical diagnostic implementation. With laboratory performance rigorously established, the clinical variables can subsequently be analyzed to define limitations, applications, and clinical utility. The role of NIST in technology evaluation for early cancer testing is described in the context of similar programs and prior experience at NIST. Here we conceptualize the validation steps of cancer test development and examine how NIST activities impact health care through institutional focus on measurement, technology, and standards development programs.
NIST-NCI Biomarkers Validation Laboratory, DNA Technologies Group, Biotechnology Division, NIST, Gaithersburg, Maryland 20899-8311, USA. peter.barker@nist.gov
Peter E
PE
Barker
D014408:Biomarkers, Tumor / Q000592:standards*; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis*; D009696:Nucleic Acids / Q000032:analysis; D012015:Reference Standards
D014408:Biomarkers, Tumor; D009696:Nucleic Acids